KPTI - Karyopharm expects FY total revenue to be ~$145.9 million
2024-01-08 12:35:53 ET
More on Karyopharm Therapeutics
- Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky
- Karyopharm reports encouraging data for endometrial cancer drug candidate
- Karyopharm Therapeutics GAAP EPS of -$0.30 misses by $0.05, revenue of $36M misses by $1.4M
- Seeking Alpha’s Quant Rating on Karyopharm Therapeutics
For further details see:
Karyopharm expects FY total revenue to be ~$145.9 million